PALI

Palisade Bio Inc

Oct 16 • 04:00PM ET

1.73

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: ONCT NRT ENTA LPTX GERN LVTX IMMP IKT HEPA

Index	-	P/E	-	EPS (ttm)	-6.16	Insider Own	0.02%	Shs Outstand	122.36M	Perf Week	-17.62%
Market Cap	211.68M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	0.00%	Shs Float	122.34M	Perf Month	199.57%
Enterprise Value	206.60M	PEG	-	EPS next Q	-0.38	Inst Own	47.47%	Short Float	0.85%	Perf Quarter	130.61%
Income	-11.85M	P/S	-	EPS this Y	83.10%	Inst Trans	-0.04%	Short Ratio	0.14	Perf Half Y	147.04%
Sales	0.00M	P/B	3.17	EPS next Y	28.16%	ROA	-121.25%	Short Interest	1.04M	Perf YTD	4.85%
Book/sh	0.55	P/C	39.06	EPS next 5Y	51.67%	ROE	-188.48%	52W High	4.32 -59.94%	Perf Year	-49.27%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	84.12% 77.35%	ROIC	-452.10%	52W Low	0.53 226.42%	Perf 3Y	-97.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.28% 19.40%	Perf 5Y	-99.94%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	69.35%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.55	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	63.07	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	82.53%	SMA20	26.00%	Beta	1.36	Target Price	8.00
Payout	-	Debt/Eq	0.13	Sales Q/Q	-	SMA50	80.22%	Rel Volume	0.73	Prev Close	1.73
Employees	8	LT Debt/Eq	0.00	Earnings	Aug 19	SMA200	82.00%	Avg Volume	7.64M	Price	1.73
IPO	Dec 20, 2006	Option/Short	No / Yes	EPS/Sales Surpr.	2.19% -	Trades		Volume	5,544,498	Change	0.00%

Oct-13-25 08:45AM	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 (GlobeNewswire) -7.50%
Oct-09-25 05:00PM	Palisade Bio Announces Cancellation of Special Meeting of Stockholders (GlobeNewswire)
Oct-02-25 04:05PM	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option (GlobeNewswire) +29.77% -5.88%
Oct-01-25 09:20AM	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +52.38%
Sep-26-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +16.20%
04:05PM	Loading…
Sep-18-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Sep-17-25 09:00AM	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data (GlobeNewswire)
Sep-05-25 08:45AM	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire)
Aug-25-25 09:00AM	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 (GlobeNewswire) -8.46%
Aug-11-25 07:04AM	Palisade reports outcomes from Phase Ib ulcerative colitis study (Clinical Trials Arena) -6.34%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.16%
09:15AM	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 (GlobeNewswire)
Jul-31-25 08:45AM	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China (GlobeNewswire)
Jul-30-25 06:30AM	PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR (PR Newswire)
Jul-23-25 08:00PM	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million (GlobeNewswire) +41.86% -9.02%
08:45AM	Loading…
Jul-22-25 08:45AM	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire) -9.20%
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-09-25 08:45AM	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors (GlobeNewswire) +5.41%
May-27-25 08:30AM	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis (GlobeNewswire)
May-06-25 08:30AM	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases (GlobeNewswire) +6.07%
May-01-25 08:30AM	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit (GlobeNewswire)
Apr-09-25 08:30AM	Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire)
Mar-14-25 08:30AM	Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM	Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM	Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM	Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM	Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM	Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM	Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM	Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
08:00AM	Loading…
Jan-16-25 08:00AM	Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Dec-17-24 08:30AM	Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board (GlobeNewswire)
Dec-13-24 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-21-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models (GlobeNewswire) -7.52%
May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 10:53PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 (InvestorPlace) -7.30%
May-07-24 08:30AM	Palisade Bio Appoints Margery Fischbein to its Board of Directors (GlobeNewswire) -6.62%
07:30AM	Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-02-24 08:30AM	Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-01-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM	Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM	Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM	Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)
Apr-11-24 09:15AM	Palisade Bio to Participate in the Virtual Investor Lunch Break Event (GlobeNewswire) +7.62%
Apr-10-24 08:15AM	Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis (GlobeNewswire) -24.91%
Apr-03-24 05:30PM	Palisade Bio Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Mar-27-24 08:00AM	Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +6.04%
Mar-26-24 11:52PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 (InvestorPlace)
Feb-15-24 08:35AM	Palisade Bio to Present at Digestive Disease Week (DDW) 2024 (GlobeNewswire)
Feb-13-24 08:35AM	Palisade Bio Provides Corporate Update and Reiterates Guidance (GlobeNewswire)
Feb-08-24 02:40PM	Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members (GlobeNewswire)
08:05AM	Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders (GlobeNewswire)
Jan-30-24 09:25AM	Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million (GlobeNewswire) -35.01%
Jan-29-24 02:01PM	Why Is Palisade Bio (PALI) Stock Up 100% Today? (InvestorPlace) +84.62%
08:05AM	Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Jan-09-24 08:00AM	Palisade Bio Selected for Poster Presentation at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Dec-29-23 04:52AM	Palisade Bio receives milestone payment for PALI-2108 development (Pharmaceutical Business Review) -9.77%
Dec-28-23 08:00AM	Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108 (GlobeNewswire) +8.98%
Nov-10-23 08:05AM	Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Sep-14-23 07:13PM	Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc (GuruFocus.com)
Sep-11-23 04:01PM	Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules (GlobeNewswire) -5.48%
08:35AM	Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-23 08:30AM	Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules (GlobeNewswire) -45.85%
Sep-06-23 08:45AM	Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease (GlobeNewswire) +108.79%
Aug-11-23 08:05AM	Palisade Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 08:05AM	Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire) -62.70%
Jul-05-23 08:45AM	Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study (GlobeNewswire)
Jun-22-23 08:30AM	PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT (PR Newswire)
Jun-14-23 08:45AM	Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-01-23 08:45AM	Palisade Bio Promotes J.D. Finley to Chief Executive Officer (GlobeNewswire) +9.09%

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Donald Allen	Director	Nov 21 '24	Option Exercise	0.00	388	0	728	Nov 22 04:00 PM
Wei Binxian	Director	Nov 21 '24	Option Exercise	0.00	388	0	855	Nov 22 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your FINVIZ experience